Day 2Wednesday, September 2, 2026 - UTC+08:00

• Delving into the transformative potential of nucleic acid-based therapies and enabling technologies, with insights into APAC’s unique investment opportunities, including emerging biotech hubs, innovative startups, and regional strengths in clinical trials and manufacturing

• Exploring collaborative investment strategies to accelerate development pipelines and expand market access for nucleic acid technologies across APAC.

• Demonstrating Abogen's unique mRNA and LNP platform
• Sharing clinical data and progress of mRNA cancer vaccines
• Accelerating preclinical and clinical development of mRNA-based T cell engagers and in vivo CAR-T

• Skin regeneration is governed by the fibroblast–extracellular matrix (ECM) axis, yet current therapies typically act indirectly on fibroblasts and yield limited or short-lived improvements in collagen content and dermal architecture.
• This presentation will discuss how RNA therapeutics can be applied in direct ECM restoration, with a particular focus on advances on trans-amplifying RNA (taRNA) technologies. It will also address current limitations of mRNA drug in regeneration medicine, and describe efforts in her group to further improve mRNA delivery, durability and functionality.

.

• Conventional in vitro transcription (IVT) has enabled the first wave of mRNA products, but important challenges remain for broader therapeutic use, including dsRNA impurities, excessive immunogenicity and/or reactogenicity, repeat-dosing limitations, scalability, and supply-chain complexity.
• This presentation will introduce Sensible Biotechnologies’ cell-based platform for mRNA design, manufacturing, and scale-up, and discuss how a cell-based production approach can enable high-purity mRNA with a favorable immunogenicity profile.
• It will also explore what this could mean for the future of mRNA therapeutics, particularly in applications where repeat dosing, high purity, low immunogenicity, and strong translational performance are critical.

• Detailing innovations in DNA template generation that significantly enhance RNA yield, achieving over 1,000-fold increases in RNA production efficiency while reducing processing steps and handling time.

• Highlighting streamlined workflows and novel methodologies that minimize cross-contamination risks and optimize the in vitro transcription (IVT) reaction for high-throughput, small-scale RNA production.

• Discussing how these advancements provide critical insights into process optimization and lay the groundwork for future scale-up and manufacturing applications.

• The COVID-19 pandemic demonstrated the promise of mRNA vaccines as a rapid-response platform, while also revealing critical gaps in global manufacturing capacity, equitable access, and timely deployment. To address these challenges and enhance preparedness for future pandemics, the International Vaccine Institute (IVI) is leading the development of DeCAFx—a Decentralized and Accelerated mRNA Vaccine Production System. DeCAFx is designed to enable scalable, regionally distributed, and time-sensitive mRNA vaccine manufacturing through modular infrastructure, standardized technologies, and pre-established technical partnerships.
• Aligned with global initiatives such as CEPI’s 100 Days Mission, DeCAFx aims to ensure vaccine production and distribution within weeks of pathogen identification. As part of this effort, IVI is advancing mRNA vaccine R&D through a global network of collaborators. These include prototype vaccines against Lassa fever (with SK bioscience) and Rift Valley fever (with Afrigen), platform validation using self-amplifying mRNA (with Karolinska Institute), and novel delivery systems such as microneedle patches (with QuadMedicine). IVI is also validating UTR-modified mRNA constructs (with Seoul National University) and evaluating an mRNA COVID-19 vaccine developed by Green Cross under KDCA support.
• Through DeCAFx, IVI aims to integrate technological innovation, regional manufacturing, and regulatory readiness to build a sustainable and equitable vaccine ecosystem capable of responding rapidly to future pandemic threats.

Highlighting the future innovation potential of RNA therapeutics, focusing on next-generation approaches such as AI-driven RNA design, RNA editing, non-coding RNAs, and circular RNAs (circRNAs) to address complex diseases and advance precision medicine in Asia-Pacific. This panel will explore how artificial intelligence is revolutionizing RNA drug discovery, target identification, and optimization of therapeutic efficacy, accelerating the development of personalized RNA-based treatments.